Simulations Plus, Inc. (NASDAQ:SLP) is a premier developer of drug discovery and development software, which is licensed to and used in drug research conducted by major pharmaceutical and biotechnology companies worldwide. The company focuses on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Simulations Plus integrates data from medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into its software, making it a leading provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit the company’s website at www.simulations-plus.com.